Athira Pharma, Inc. (ATHA)
$
0.36
-0.02 (-5.56%)
Key metrics
Financial statements
Free cash flow per share
-1.8085
Market cap
14.2 Million
Price to sales ratio
14.6675
Debt to equity
0.0318
Current ratio
10.8078
Income quality
1.1812
Average inventory
0
ROE
-1.3940
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company that focuses on developing small molecules aimed at restoring neuronal health and slowing neurodegradation. The company achieved a revenue of $0.00 indicating its niche market focus. Athira's lead product candidate, ATH-1017, is a blood-brain barrier-penetrating small molecule HGF/MET positive modulator currently undergoing LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for Alzheimer's disease treatment, as well as Phase 2 clinical trials for Parkinson's disease. In addition, the company has product candidates in the preclinical stage, including ATH-1019 for peripheral nervous system indications and ATH-1020 for neuropsychiatric conditions. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations, while also recording an income tax expense of $0.00 indicating its tax obligations. Furthermore, Athira Pharma recorded an operating income of -$100,902,000.00 reflecting its earnings from core operations, and earned an interest income of $3,962,000.00 showcasing its financial investments. Established in 2011 and headquartered in Bothell, Washington, Athira Pharma was formerly known as M3 Biotechnology, Inc., a name it adopted in April 2019. Athira Pharma's stock is affordable at $0.36 making it suitable for budget-conscious investors. The stock enjoys a high average trading volume of 196,890.00 indicating strong liquidity in the market. With a market capitalization of $14,198,148.00 the company is classified as a small-cap player, which allows for potential growth within the sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Athira belongs to the Healthcare sector, driving innovation and growth through its development of promising therapeutic candidates.
Is Athira Pharma, Inc. (ATHA) a good investment?
Investing in Athira Pharma, Inc. (ATHA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Athira Pharma, Inc. (ATHA)'s stock forecast?
Analysts predict Athira Pharma, Inc. stock to fluctuate between $0.22 (low) and $0.83 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Athira Pharma, Inc.'s market capitalization?
As of 2025-09-15, Athira Pharma, Inc.'s market cap is $14,198,148, based on 39,439,300 outstanding shares.
How does Athira Pharma, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Athira Pharma, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Athira Pharma, Inc. (ATHA) stock?
To buy Athira Pharma, Inc. (ATHA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATHA. Place an order (Market, Limit, etc.).
What is the best time to invest in Athira Pharma, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Athira Pharma, Inc. stock ever split?
Athira Pharma, Inc.'s last stock split was 1:10 on 2025-09-18.
How did Athira Pharma, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.52 | Growth: -18.45%.
Where can I find Athira Pharma, Inc.'s investor relations reports?
Visit https://www.athira.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Athira Pharma, Inc.?
You can explore historical data from here
What is the all-time high and low for Athira Pharma, Inc. stock?
All-time high: $16.65 (2021-11-12) | All-time low: $0.22 (2025-04-08).
What are the key trends affecting Athira Pharma, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira's issued and authorized common stock. Athira's stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company's Annual Meeting of Stockholders held on May 29, 2025.
accessnewswire.com
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / September 10, 2025 / ATHA Energy Corp. (TSX.V:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company"), as a result of a review by the British Columbia Securities Commission, the Company is issuing the following news release to clarify certain disclosure. The Company announces today that it has filed: (i) an updated technical report in respect of its CMB property located in Newfoundland and Labrador, Canada dated July 8, 2025 and effective June 14, 2025 entitled "NI 43-101 Technical Report, Central Mineral Belt Property, Newfoundland and Labrador, Canada" prepared by Stefan Kruse, Ph.D.
accessnewswire.com
EXCELSIOR SPRINGS FULLY FUNDED FOR 2025 DRILLING PROGRAM WHITE ROCK, BC / ACCESS Newswire / August 22, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to announce that, further to its news release dated June 2, 2025, Mammoth Minerals Limited (ASX:M79) (formerly, Firetail Resources Limited) ("Mammoth" or "M79") has exercised its option to be able to earn an 80% interest in Athena's Excelsior Springs project in Nevada, USA (the "Excelsior" project), effective August 19, 2025 (the "Exercise Date"). In consideration.
fool.com
Athira Pharma (ATHA -2.38%), a biopharmaceutical company developing drugs for neurodegenerative diseases, released its second quarter results on August 7, 2025. The update centered on its cost containment, strategic pipeline refocus, and progress with its lead candidate, ATH-1105.
accessnewswire.com
HIGHLIGHTS Completes first two drill holes of its 2025 Angilak Exploration Program comprising ~10,000m of diamond drilling. KU Discovery Target: The maiden drill hole, KU-DD-001 successfully targeted stacked gravity and structural anomalies (Figure 2), intersecting shallow high-grade uranium mineralization as well as numerous zones of lower-grade mineralization throughout the hole.
accessnewswire.com
HIGHLIGHTS The 2025 Angilak Exploration Program will comprise ~10,000 m of diamond drilling with two objectives: Lac 50 Deposit - expansion of the footprint of uranium mineralization. Stepping out along strike and at depth from the 2024 Exploration Target (as defined below), which remains open and unconstrained.
accessnewswire.com
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 22, 2025 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company") is pleased to announce that, further to its press releases dated March 31, 2025 and April 7, 2025, it has completed a fully-subscribed private placement offering of: (i) 16,766,490 flow-though common shares of the Company ("FT Shares") at a price of $0.47 per FT Share; and (ii) 3,475,000 FT Shares that may be immediately resold or donated to registered charities ("Charity FT Shares", and collectively with the FT Shares, the "Offered Shares") at a price of $0.61 per Charity FT Share for aggregate gross proceeds of approximately $10,000,000(the "Offering").
See all news
